BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 9544517)

  • 1. Prediction of cumulative incidence function under the proportional hazards model.
    Cheng SC; Fine JP; Wei LJ
    Biometrics; 1998 Mar; 54(1):219-28. PubMed ID: 9544517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
    Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR
    J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Applying Cox regression to competing risks.
    Lunn M; McNeil D
    Biometrics; 1995 Jun; 51(2):524-32. PubMed ID: 7662841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time-dependent covariates in the proportional subdistribution hazards model for competing risks.
    Beyersmann J; Schumacher M
    Biostatistics; 2008 Oct; 9(4):765-76. PubMed ID: 18434297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sample size calculations in the presence of competing risks.
    Latouche A; Porcher R
    Stat Med; 2007 Dec; 26(30):5370-80. PubMed ID: 17955563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An EM-based semi-parametric mixture model approach to the regression analysis of competing-risks data.
    Ng SK; McLachlan GJ
    Stat Med; 2003 Apr; 22(7):1097-111. PubMed ID: 12652556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dealing with competing risks: testing covariates and calculating sample size.
    Pintilie M
    Stat Med; 2002 Nov; 21(22):3317-24. PubMed ID: 12407674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimates of clinically useful measures in competing risks survival analysis.
    Ambrogi F; Biganzoli E; Boracchi P
    Stat Med; 2008 Dec; 27(30):6407-25. PubMed ID: 18937229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment effects in competing-risks analysis of prostate cancer data.
    Kay R
    Biometrics; 1986 Mar; 42(1):203-11. PubMed ID: 3521753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SAS macros for estimation of the cumulative incidence functions based on a Cox regression model for competing risks survival data.
    Rosthøj S; Andersen PK; Abildstrom SZ
    Comput Methods Programs Biomed; 2004 Apr; 74(1):69-75. PubMed ID: 14992828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating cardiovascular mortality in type 2 diabetes patients: an analysis based on competing risks Markov chains and additive regression models.
    Rosato R; Ciccone G; Bo S; Pagano GF; Merletti F; Gregori D
    J Eval Clin Pract; 2007 Jun; 13(3):422-8. PubMed ID: 17518809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Semiparametric models for cumulative incidence functions.
    Bryant J; Dignam JJ
    Biometrics; 2004 Mar; 60(1):182-90. PubMed ID: 15032788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Confidence intervals for median survival times under a piecewise exponential model with proportional hazards covariate effects.
    Karrison T
    Stat Med; 1996 Jan; 15(2):171-82. PubMed ID: 8614753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Applying k-sample tests to conditional probabilities for competing risks in a clinical trial.
    Lunn M
    Biometrics; 1998 Dec; 54(4):1662-72. PubMed ID: 9988543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estrogen and survival data in carcinoma of the prostate.
    Bennett AH; Dowd JB; Harrison JH
    Surg Gynecol Obstet; 1970 Mar; 130(3):505-8. PubMed ID: 4905115
    [No Abstract]   [Full Text] [Related]  

  • 16. Prostate-specific antigen velocity and survival for patients with hormone-refractory metastatic prostate carcinoma.
    Rozhansky F; Chen MH; Cox MC; Dahut W; Figg WD; D'Amico AV
    Cancer; 2006 Jan; 106(1):63-7. PubMed ID: 16333854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cause-specific cumulative incidence estimation and the fine and gray model under both left truncation and right censoring.
    Geskus RB
    Biometrics; 2011 Mar; 67(1):39-49. PubMed ID: 20377575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modelling competing risks in cancer studies.
    Klein JP
    Stat Med; 2006 Mar; 25(6):1015-34. PubMed ID: 16435339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Competing risks analysis of patients with osteosarcoma: a comparison of four different approaches.
    Tai BC; Machin D; White I; Gebski V;
    Stat Med; 2001 Mar; 20(5):661-84. PubMed ID: 11241570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A simple test for independent censoring under the proportional hazards model.
    Lee SY; Wolfe RA
    Biometrics; 1998 Sep; 54(3):1176-82. PubMed ID: 9840972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.